According to Zhitong Finance App News, Sannuo Biotech (300298.SZ) released its 2026 semi-annual report. In the first half of 2026, the company achieved operating income of 2,537 billion yuan, an increase of 12.08%; net profit attributable to shareholders of listed companies of 221 million yuan, an increase of 22.52% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of 210 million yuan, an increase of 32.87% year on year; basic earnings per share were 0.4096 yuan.

During the reporting period, the company adhered to the belief of “constant change and evergreen”, with “simplification, AI, and delivery” as the fulcrum of action, and insisted on focusing on the main business of rapid chronic disease testing with blood sugar monitoring products as the core, promoting the company's overall human efficiency and management improvement. At the same time, it continued to focus on the three major directions of specialization, digital intelligence, and globalization. It was committed to innovation in product technology and the digital intelligence of management systems, and promoted the implementation of key tasks to promote steady growth in the company's overall sales revenue and operating profit.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.